Mutagenesis of the CTX-M-type ESBL-is MIC-guided treatment according to the new EUCAST recommendations a safe approach?

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2528-2535

  Ramos, João M Costa ^a   Stein, Claudia ^a   Pfeifer, Yvonne ^b   Brandt, Christian ^a   Pletz, Mathias W ^a   Makarewicz, Oliwia ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 1; BETA LACTAMASE CTX M 14; BETA LACTAMASE CTX M 15; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; BETA-LACTAMASE CTX-M-14; BETA-LACTAMASE CTX-M-15; BETA-LACTAMASE TEM-3;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE EXPRESSION; GENE SEQUENCE; GROWTH RATE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MUTAGENESIS; MUTATION RATE; NONHUMAN; PHENOTYPE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETIC SELECTION; GENETIC TRANSCRIPTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; PLASMID; PRACTICE GUIDELINE; SECRETION (PROCESS);

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; GENE EXPRESSION PROFILING; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS; MUTATION RATE; PLASMIDS; PRACTICE GUIDELINES AS TOPIC; SELECTION, GENETIC; TRANSCRIPTION, GENETIC;

EID: 84954285516     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv153     Document Type: Article

References (41)

1. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 2010; 300: 371-9.
2. Bush K. Alarming β-lactamase-mediated resistance inmultidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 2010; 13: 558-64.
3. Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012; 39: 283-94.
4. Rawat D, Nair D. Extended-spectrum β-lactamases in Gram negative bacteria. J Glob Infect Dis 2010; 2: 263-74.
5. Leclercq R, Canton R, Brown DF et al. EUCASTexpert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 2013; 19: 141-60.
6. Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005; 11 Suppl 6: 10-7.
7. Maglio D, Ong C, Banevicius MA et al. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum β-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother 2004; 48: 1941-7.
8. Livermore DM, Andrews JM, Hawkey PM et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012; 67: 1569-77.
9. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
10. Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev 2014; 27: 543-74.
11. Kennedy K, Collignon P. Colonisation with Escherichia coli resistant to 'critically important' antibiotics: a high risk for international travellers. Eur J Clin Microbiol Infect Dis 2010; 29: 1501-6.
12. van der Bij AK, Pitout JD. The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. J Antimicrob Chemother 2012; 67: 2090-100.
13. Carlet J, Collignon P, Goldmann D et al. Society's failure to protect a precious resource: antibiotics. Lancet 2011; 378: 369-71.
14. Goossens H, Ferech M, Vander Stichele R et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365: 579-87.
15. Son JS, Song JH, Ko KS et al. Bloodstream infections and clinical significance of healthcare-associated bacteremia: a multicenter surveillance study in Korean hospitals. J Korean Med Sci 2010; 25: 992-8.
16. Rodriguez-Bano J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407-14.
17. Valenza G, Nickel S, Pfeifer Y et al. Extended-spectrum β-lactamase-producing Escherichia coli as intestinal colonizers in the German community. Antimicrob Agents Chemother 2014; 58: 1228-30.
18. Canton R, Coque TM. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006; 9: 466-75.
19. Bonnet R, Dutour C, Sampaio JL et al. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240-.Gly. Antimicrob Agents Chemother 2001; 45: 2269-75.
20. Poirel L, Naas T, Le Thomas I et al. CTX-M-type extended-spectrum β-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob Agents Chemother 2001; 45: 3355-61.
21. Vanhove M, Houba S, Lamotte-Brasseur J et al. Probing the determinants of protein stability: comparison of class A β-lactamases. Biochem J 1995; 308 (Pt 3): 859-64.
22. Eller C, Simon S, Miller T et al. Presence of β-lactamases in extended-spectrum-cephalosporin-resistant Salmonella enterica of 30 different serovars in Germany 2005-11. J Antimicrob Chemother 2013; 68: 1978-81.
23. Stein C, Makarewicz O, Bohnert J et al. Three dimensional checkerboard synergy analysis of colistin, meropenem, tigecycline against multidrugresistant clinical Klebsiella pneumoniae isolates. PLoS One 2015; doi:10.1371/journal.pone.0126479.
24. Stein C, Makarewicz O, Pfeifer Y et al. Direct RNA-based detection and differentiation of CTX-M-type extended-spectrum β-lactamases (ESBL). PLoS One 2013; 8: e80079.
25. Dalgaard P, Ross T, Kamperman L et al. Estimation of bacterial growth rates from turbidimetric and viable count data. Int J Food Microbiol 1994; 23: 391-404.
26. Monod J. The growth of bacterial cultures. Annu Rev Microbiol 1949; 3: 371-94.
27. Poirel L, Gniadkowski M, Nordmann P. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J Antimicrob Chemother 2002; 50: 1031-4.
28. Kohanski MA, DePristo MA, Collins JJ. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell 2010; 37: 311-20.
29. Kohanski MA, Dwyer DJ, Hayete B et al. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 2007; 130: 797-810.
30. Fernandez L, Hancock RE. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 2012; 25: 661-81.
31. De la Cruz MA, Calva E. The complexities of porin genetic regulation. J Mol Microbiol Biotechnol 2010; 18: 24-36.
32. Adler M, Anjum M, Andersson DI et al. Influence of acquired β-lactamases on the evolution of spontaneous carbapenem resistance in Escherichia coli. J Antimicrob Chemother 2013; 68: 51-9.
33. Kaern M, Elston TC, Blake WJ et al. Stochasticity in gene expression: from theories to phenotypes. Nat Rev Genet 2005; 6: 451-64.
34. Dutour C, Bonnet R, Marchandin H et al. CTX-M-1, CTX-M-3, and CTX-M-14 β-lactamases from Enterobacteriaceae isolated in France. Antimicrob Agents Chemother 2002; 46: 534-7.
35. Tzouvelekis LS, Tzelepi E, Tassios PT et al. CTX-M-type β-lactamases: an emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 2000; 14: 137-42.
36. Barlow M, Hall BG. Experimental prediction of the natural evolution of antibiotic resistance. Genetics 2003; 163: 1237-41.
37. Taccone FS, Laterre PF, Dugernier T et al. Insufficient b-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14: R126.
38. Perez-Trallero E, Alkorta M, Garcia-Arenzana JM et al. In-vitro, in-vivo and ex-vivo studies with oral β-lactams against Streptococcus pneumoniae. J Antimicrob Chemoth 1998; 41: 629-34.
39. Ho PL, Chan WM, Tsang KW et al. Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002; 34: 567-73.
40. Paterson DL, Ko WC, Von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
41. Kang CI, Cha MK, Kim SH et al. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria. Int J Antimicrob Agents 2014; 43: 456-9.